Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group

Advanced ovarian carcinoma in early progression (<6 months) (AOCEP) is considered resistant to most cytotoxic drugs. Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity in relapsed ovarian cancer. Their combination was tested in patients with AOCEP in phase II study. Fifty pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray-Coquard, I, Weber, B, Cretin, J, Haddad-Guichard, Z, Lévy, E, Hardy-Bessard, A C, Gouttebel, M C, Geay, J-F, Aleba, A, Orfeuvre, H, Agostini, C, Provencal, J, Ferrero, J M, Fric, D, Dohollou, N, Paraiso, D, Salvat, J, Pujade-Lauraine, É
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653739/
https://www.ncbi.nlm.nih.gov/pubmed/19190632
http://dx.doi.org/10.1038/sj.bjc.6604878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653739/
https://www.ncbi.nlm.nih.gov/pubmed/19190632
http://dx.doi.org/10.1038/sj.bjc.6604878

Ejemplares similares